



# Contents

- 1. Identification of high risk-AML patients** 1  
*Matteo G. Della Porta, Alessia Campagna*
- 2. Diagnostic procedures** 15  
*Tiziana Ottone, Serena Travaglini, Luca Guarnera, Mariadomenica Divona, Paola Panetta, Carmelo Gurnari, Maria Teresa Voso*
- 3. Patient-related factors: how do we define fitness?** 44  
*Felicitto Ferrara*
- 4. Current therapy for fit patients** 56  
*Fabio Guolo, Paola Minetto, Roberto M. Lemoli*
- 5. Current therapy for older/unfit patients** 71  
*Luca Guarnera, Fabrizio Bonanni, Raffaele Palmieri, Adriano Venditti*
- 6. Factors after diagnosis: the role of measurable residual disease** 93  
*Sylvie Freeman*

<b>7. Allogeneic stem cell transplantation</b>	<b>110</b>
<i>Fabio Ciceri</i>	
<b>8. Risk of infectious complications with novel therapies for high-risk acute myeloid leukemia</b>	<b>127</b>
<i>Luana Fianchi, Martina Quattrone, Livio Pagano</i>	
<b>9. High-risk acute myeloid leukemia: from the immune microenvironment to immunotherapy</b>	<b>151</b>
<i>Gianluca Cristiano, Darina Ocadlikova, Antonio Curti</i>	
<b>10. Emerging targeted therapies for high-risk acute myeloid leukemia</b>	<b>171</b>
<i>Gautam Borthakur</i>	
<b>11. Emerging approaches to treat high-risk acute myeloid leukemia</b>	<b>190</b>
<i>Abhishek Maiti, Michael Andreeff</i>	